+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Proton pump inhibitors use and change in bone mineral density



Proton pump inhibitors use and change in bone mineral density



International Journal of Rheumatic Diseases 19(9): 864-868



Limited data are available reporting the effect of proton pump inhibitor (PPI) use on changes in bone mineral density (BMD). The aim of this study was to investigate the relationship between PPI use and BMD. The current cross-sectional study included 80 patients (31 male and 49 female) aged 20-45 years old without history of hip fracture with a follow-up of at least 2 years. The study was carried out in 40 daily PPI users and 40 PPI non-users. Femur and posterior-anterior spine BMD were quantified by dual-energy X-ray absorptiometry in all participants. The relationship between use of PPI and BMD was tested by multivariate linear regression analysis adjusted for age, sex, BMI and serum vitamin D levels. Our study demonstrated that mean femoral T-scores were significant between PPI and non-user groups (-0.44 ± 1.11 vs. +0.19 ± 0.95, P = 0.007). In addition, the frequency of femoral osteoporosis and osteopenia in the exposed group was significantly more in the control group (P = 0.04). Mean femoral Z-scores, lumbar spine T-score and lumbar spine Z-score were not statistically different between PPI and non-user groups. The linear regression analysis revealed that there was no association between PPI and non-users, and lumbar spine T-score. Overall, the results of this study showed that PPI use in subjects without risk factors of osteoporosis determined by the femoral T-score compared with the control group was associated with increased risk of developing osteoporosis and osteopenia in the femur bones.

(PDF emailed within 0-6 h: $19.90)

Accession: 058654658

Download citation: RISBibTeXText

PMID: 27242025

DOI: 10.1111/1756-185X.12866


Related references

Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study. Evidence-Based Medicine 18(5): 192-193, 2014

Effect of long-term proton pump inhibitors on bone mineral density. La Tunisie Medicale 96(3): 193-197, 2018

Correlation of Bone Mineral Density Scores and Proton Pump Inhibitors Use in the Elderly. Current Rheumatology Reviews 12(2): 162-166, 2017

Fracture risk and bone mineral density reduction associated with proton pump inhibitors. PharmacoTherapy 32(1): 67-79, 2012

Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors. Biomedical Reports 5(2): 165-170, 2016

Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. Journal of Bone and Mineral Research 30(2): 232-239, 2016

Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Archives of Internal Medicine 170(9): 765-771, 2010

Bone density in proton pump inhibitors users: a prospective study. Rheumatology International 33(9): 2255-2260, 2014

Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138(3): 896-904, 2010

Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone 57(2): 437-442, 2014

Long-term therapy with proton pump inhibitors is associated with decreased bone density. Medical Hypotheses 72(5): 608-609, 2009

Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients. International Journal of Clinical Practice 63(2): 261-268, 2010

Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study. Journal of Gastroenterology 2019, 2019

Change of bone mineral density and relationship between bone mineral density and tumor necrosis factor-alpha, nitric oxide in the type 2 diabetes mellitus. Journal of China Medical University 31(2): 106-107, 2002

Prevention of stress induced ulcers: histamine-2 receptor antagonists or proton pump inhibitors? - gastric hemorrhage occur more often under proton pump inhibitors. Deutsche Medizinische Wochenschrift 139(25-26): 1338, 2014